[company_age]unknown[/company_age][employees]2-10 employees[/employees][funding]Pre seed[/funding][description]Orpha Biotech is a pharmaceutical company dedicated to developing innovative solutions for rare diseases, particularly those with no effective treatment options. They focus on orphan diseases, which are characterized by low incidence and limited market size, often neglected by mainstream drug developers. Orpha Biotech's mission is to alleviate the burden of these diseases by providing patients with access to effective therapies. Their approach involves targeting central molecular determinants and biological mechanisms of disease pathogenesis, utilizing structure-based computational 'virtual screening' and allied docking simulations to generate a platform of small molecules for potential development as agonist or antagonist NCEs. Their initial focus is on orphan autoimmune indications, particularly systemic sclerosis, where they have developed novel antifibrotic agents that go beyond inhibiting disease progression to promoting tissue regeneration and repair. Orpha Biotech's endeavors are supported by the well-established commercial market for orphan products, which offers a streamlined, expedited, and cheaper regulatory approval process compared to regular medicines. This allows them to accelerate the delivery of treatments to patients across the globe.[/description][ps]Development of innovative solutions for the treatment of rare diseases, particularly orphan autoimmune indications.[/ps]